Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Yate-Ching Yuan"'
Autor:
Zheng Liu, Karen S. Aboody, Connor Burke, Min Li, Yuman Fong, Jianming Lu, Yate-Ching Yuan, Rachael Mooney, Jennifer Batalla-Covello, Yvonne R. Cornejo, Asma Abdul Majid, Mohamed Hammad, Thanh H. Dellinger, Nanhai G. Chen
Publikováno v:
Molecular Therapy: Oncolytics, Vol 18, Iss, Pp 326-334 (2020)
Molecular Therapy Oncolytics
Molecular Therapy Oncolytics
Oncolytic virotherapy represents a promising approach for treating recurrent and/or drug-resistant ovarian cancer. However, its successful application in the clinic has been hampered by rapid immune-mediated clearance, which reduces viral delivery to
Autor:
Maria Hahn, Yanghee Woo, Annie Yang, Haiqing Li, Yuman Fong, Yate-Ching Yuan, Carolyn E. Behrendt, Ajay Goel
Publikováno v:
Journal of the American College of Surgeons. 232(4)
Background Precision oncology can identify patient-specific molecular signatures to better inform the prognosis and management of surgical cancer patients. Specifically, microRNAs (miRs) hold promise as prognostic biomarkers because dysregulation of
Autor:
Yate-Ching Yuan, Ajay Goel, Laleh G. Melstrom, Lily L. Lai, Yanghee Woo, Mustafa Raoof, Yuman Fong, Philip H.G. Ituarte, I. Benjamin Paz, Haiqing Li, Amir Ali Khan
Publikováno v:
Annals of surgical oncology. 28(2)
The rise in the incidence of gastric cancer (GC) and colorectal cancer (CRC) in young adults (YA) remains unexplained. We aim to identify differences in these malignancies between YA and older patients. We retrospectively analyzed the California Canc
Autor:
Khyatiben V. Pathak, Patrick Pirrotte, Charles K. Hu, Krystine Garcia-Mansfield, Emmanuel Menashi, Frederic Zenhausern, Zahra Eftekhari, Karen Lewandoski, Marissa McGilvrey, Yate Ching Yuan
Publikováno v:
Molecular & Cellular Proteomics : MCP
Unlike bronchoalveolar lavages (BAL), the molecular composition of more readily accessible endotracheal aspirates (ETA) has been poorly studied in the context of ventilator-associated pneumonia. In this work, longitudinal ETA and BAL collections from
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5dea812ff21d0a842ec8f4fe269cd57
Autor:
J Waisman, Daniel Schmolze, Norma Martinez, Aileen Tang, G. Somlo, Susan E. Yost, Peter P. Lee, S Apple, B Mendez, Mina S. Sedrak, Joanne E. Mortimer, N Tank, Paul Frankel, Timothy W. Synold, Yate-Ching Yuan, Arti Hurria
Publikováno v:
Cancer Research. 78:OT1-05
Background: Androgen receptor (AR) targeted therapy and immunotherapy represent one of the most promising strategies for metastatic triple negative breast cancer (mTNBC), which accounts for 15-20% of all breast cancers. As a nonsteroidal selective an
Autor:
Y Yuan, Yate-Ching Yuan, Zheng Liu, Joanne E. Mortimer, Paul Frankel, Susan E. Yost, S Nicola
Publikováno v:
Cancer Research. 77:P6-16
Background: Next-Generation Sequencing (NGS) has made genomic mutation-driven cancer medicine feasible. Recognizing the importance of pathway and biomarker-driven personalized therapy for patients with metastatic breast cancer (MBC), we frequently su
Autor:
Susan E. Yost, Zheng Liu, Yate-Ching Yuan, Y Liang, Y Yuan, Angela Ying-Jian Li, Charles Warden, Peiguo G. Chu, Xiwei Wu, L Goldstein, Jerry Wang
Publikováno v:
Cancer Research. 77:P1-05
Background: Triple negative breast cancer (TNBC) is a heterogeneous disease with several molecular subtypes: basal-like1 (BL1), basal-like 2 (BL-2), mesenchymal(M), mesenchymal-stem-like(MSL), immune-modulatory(IM) and unclassified (UNC) Molecular ev
Autor:
Susan L. Neuhausen, Joanne E. Mortimer, Yuan Yuan, Sumanta K. Pal, Paul Frankel, Ravi Salgia, Nicola M. Solomon, John H. Yim, Isa Mambetsariev, Yate-Ching Yuan, Susan E. Yost
Publikováno v:
Oncotarget
// Yuan Yuan 1 , Susan E. Yost 1 , John Yim 3 , Yate-Ching Yuan 2 , Nicola M. Solomon 1 , Isa Mambetsariev 1 , Sumanta Pal 1 , Paul Frankel 4 , Ravi Salgia 1 , Susan L. Neuhausen 5 and Joanne Mortimer 1 1 Department of Medical Oncology & Molecular Th
Autor:
Travis Y. Tu, Daniel Schmolze, Yate-Ching Yuan, Anthony Rosario, Roger Wang, Peiguo Chu, Susan E. Yost, T-F He, Peter P. Lee
Publikováno v:
Cancer Research. 78:P3-05
Background: Triple negative breast cancer (TNBC) is a heterogeneous disease with several molecular subtypes: basal-like1 (BL-1), basal-like 2 (BL-2), mesenchymal (M), and luminal androgen receptor (LAR). Molecular evolution of TNBC through chemothera
Publikováno v:
Journal of Clinical Oncology. 39:474-474
474 Background: Advanced/metastatic urothelial carcinoma (UC) is a significant public health burden with median overall survival of 15 months. Although, immune checkpoint inhibitors (ICI) have provided an additional second line treatment option, only